Prostate Specific Membrane Antigen PET Imaging

A breakthrough in diagnostic imaging for prostate cancer treatment

Our new prostate-specific membrane antigen (PSMA) PET imaging technology significantly improves how prostate cancer is detected and treated.

PSMA PET imaging is used for the initial staging of prostate cancer and restaging of recurrent prostate cancer.

What is PSMA PET?

PSMA PET provides high-quality images and more specificity for detecting prostate cancer than traditional imaging, giving radiation oncologists the ability to find and treat prostate cancer more effectively.

In fact, according to the National Cancer Institute, the PSMA PET scan is 27% more accurate than standard imaging approaches, based on its sensitivity and specificity. Sensitivity measures how well a test can detect a specific disease or condition. Specificity refers to the ability of a test to confirm a person has a particular condition. The higher a test's specificity, the fewer false positives.

How does PSMA PET work?

For the PSMA PET scan, a radioactive tracer drug is injected and attaches to PSMA proteins (prostate cancer tumors overexpress this protein).

The PET scan detects the concentrated PSMA tracer, pinpointing these tumors for more effective treatment.

For more information, contact Rocky Mountain Cancer Centers' radiation department at 303-385-2068 or 303-385-2029.